Who is sponsoring NCT01843426?

NCT01843426 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT01843426?

Interventions in NCT01843426: Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan.

What condition does NCT01843426 study?

NCT01843426 studies Aortic Valve Stenosis.

Is NCT01843426 still recruiting?

NCT01843426 is currently completed. Last updated 31 July 2018.

Last reviewed 2018-07-31 · How we verify

NCT01843426

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Image Quality and Safety of Low-Volume, Low-Concentration, Iso-Osmolar Contrast Medium in the Computed Tomographic Workup of Patients Considered for TAVR

Completed NA Last updated 31 July 2018

What this trial tests

NA trial testing Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan in Aortic Valve Stenosis in 40 participants. Completed in 25 September 2017.

Timeline

1 February 2013

Primary endpoint
25 September 2017

25 September 2017

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	1 February 2013
Primary completion	25 September 2017
Estimated completion	25 September 2017
Sites	1 location across United States

Drugs / interventions tested

Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan — full drug profile →

Conditions studied

Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →

Sponsor

Medical University of South Carolina

Who can join

Adults 18 to 90, any sex, with Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinically Diagnostic CT Assessments
Time frame: up to 2 years
Determine that restricting the contrast media volume to 60ml of 270 mgI/ml iodixanol or less generates clinically diagnostic CT assessments prior to TAVR.

Sponsor's own description

The purpose of this study is to evaluate contrast media volume, safety and 30-day outcome of patients after a computed tomography (CT) scan. The results of this study will help to determine the minimum volume of contrast material that can be used to ensure patient safety while not compromising diagnostic image quality in high-risk patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Aortic Valve Stenosis

Currently open trials in the same condition.

NCT07455292 — Phenotyping Left Ventricle Failure With Hemodynamic Biomarkers From 4D Flow Magnetic Resonance Imaging · NA · recruiting
NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
NCT07145463 — Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aorti · NA · recruiting
NCT07520656 — Impact of Transcatheter Aortic Valve Implantation and Mitral Valve Repair on Sleep-Disordered Breathing · recruiting
NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01843426 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 31 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01843426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing